Stay updated on SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Sign up to get notified when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.

Latest updates to the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page footer now displays Revision: v3.6.3, replacing Revision: v3.6.2, indicating a minor platform update.SummaryDifference0.0%

- Check19 days agoChange DetectedThe record history page now displays Revision: v3.6.2 instead of Revision: v3.6.0. This reflects a new version tag for the page's history content.SummaryDifference0.0%

- Check34 days agoChange DetectedThe record history shows the recruitment status changed from Active, not recruiting to Completed with a No longer looking for participants note; new status entries were added on 2026-06-04 and 2026-06-08, and the revision updated to v3.6.0.SummaryDifference0.6%

- Check41 days agoChange DetectedThe revision label on the page updated from v3.5.4 to v3.5.5, indicating a software update to the page. This change does not alter study data or user-facing functionality.SummaryDifference0.0%

- Check62 days agoChange DetectedFooter release tag updated to Revision: v3.5.4, reflecting a new platform version for the history page. The underlying study information remains unchanged.SummaryDifference0.0%

- Check83 days agoChange DetectedThe page’s footer/application version was updated from **v3.5.2** to **v3.5.3** for the ClinicalTrials.gov interface.SummaryDifference0.0%

Stay in the know with updates to SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Daratumumab in High-Risk Smoldering Multiple Myeloma Clinical Trial page.